Atom Investors LP Cuts Stake in Urogen Pharma $URGN

Atom Investors LP lowered its position in Urogen Pharma (NASDAQ:URGN) by 19.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 234,423 shares of the company’s stock after selling 57,539 shares during the quarter. Atom Investors LP’s holdings in Urogen Pharma were worth $5,490,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. boosted its stake in Urogen Pharma by 27.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock worth $53,000 after buying an additional 486 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in Urogen Pharma by 1,594.4% in the third quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock worth $66,000 after buying an additional 3,125 shares in the last quarter. Osaic Holdings Inc. boosted its stake in Urogen Pharma by 491.2% in the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock worth $50,000 after buying an additional 3,070 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in Urogen Pharma by 422.0% in the second quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company’s stock worth $94,000 after buying an additional 5,571 shares in the last quarter. Finally, ProShare Advisors LLC purchased a new stake in Urogen Pharma in the fourth quarter worth approximately $206,000. Hedge funds and other institutional investors own 91.29% of the company’s stock.

Insider Buying and Selling at Urogen Pharma

In other news, insider Mark Schoenberg sold 5,222 shares of the stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $27.30, for a total transaction of $142,560.60. Following the completion of the sale, the insider owned 139,763 shares of the company’s stock, valued at approximately $3,815,529.90. This represents a 3.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 4.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on URGN. LADENBURG THALM/SH SH began coverage on Urogen Pharma in a research note on Monday, May 11th. They issued a “buy” rating and a $43.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and issued a $45.00 target price on shares of Urogen Pharma in a research note on Wednesday, June 3rd. Jefferies Financial Group raised Urogen Pharma to a “strong-buy” rating in a research note on Friday, April 24th. D. Boral Capital reaffirmed a “buy” rating and issued a $33.00 target price on shares of Urogen Pharma in a research note on Tuesday, March 31st. Finally, Oppenheimer reaffirmed an “outperform” rating on shares of Urogen Pharma in a research note on Tuesday, June 2nd. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $39.50.

Urogen Pharma Stock Performance

NASDAQ:URGN opened at $31.95 on Wednesday. The firm has a market cap of $1.56 billion, a PE ratio of -11.62 and a beta of 1.59. Urogen Pharma has a fifty-two week low of $12.73 and a fifty-two week high of $32.37. The business has a 50 day moving average price of $26.23 and a 200-day moving average price of $22.88.

Urogen Pharma (NASDAQ:URGN) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.01. The company had revenue of $50.96 million for the quarter, compared to analysts’ expectations of $44.83 million. Research analysts predict that Urogen Pharma will post -0.98 EPS for the current year.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.